Literature DB >> 3029597

Retroviral transduction of T-cell antigen receptor beta-chain and myc genes.

R Fulton, D Forrest, R McFarlane, D Onions, J C Neil.   

Abstract

Support for multistage models of oncogenesis has been provided by several highly leukaemogenic retrovirus isolates that have transduced more than one host cell gene. Where functional studies have been performed, these retroviral oncogenes show synergy for in vitro transformation and leukaemogenesis. In naturally occurring feline leukaemias associated with feline leukaemia virus (FeLV), retroviral transduction of myc is a frequent oncogenic mechanism. But evidence suggesting that the FeLV v-myc genes might be insufficient for leukaemogenesis was provided by the latency (12 weeks) and clonality of FeLV/v-myc-induced tumours and the absence of demonstrable in vitro transformation by these viruses. In the search for secondary leukaemogenic events in FeLV/v-myc tumours, we have identified a case of FeLV transduction of a T-cell antigen receptor beta-chain gene. The proviruses carrying this gene (which we have named v-tcr) were a separate population from those carrying v-myc. In its normal role, the T-cell receptor beta-chain forms part of a multimeric complex involved in antigen recognition and T-cell activation. We suggest that v-tcr is a novel viral oncogene which assisted v-myc in the genesis of a naturally occurring case of thymic lymphosarcoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029597     DOI: 10.1038/326190a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  22 in total

1.  Meeting report. Report of meeting of Section of Clinical Immunology and Allergy, 11 March 1991.

Authors: 
Journal:  J R Soc Med       Date:  1992-02       Impact factor: 5.344

2.  Transduction of cellular neo mRNA by retrovirus-mediated recombination.

Authors:  H Stuhlmann; M Dieckmann; P Berg
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Multiple phenotypes associated with Myc-induced transformation of chick embryo fibroblasts can be dissociated by a basic region mutation.

Authors:  D H Crouch; R Gallagher; C R Goding; J C Neil; R Fulton
Journal:  Nucleic Acids Res       Date:  1996-08-15       Impact factor: 16.971

Review 4.  Receptor-mediated leukaemogenesis: hypothesis revisited.

Authors:  J C Neil; R Fulton; R McFarlane; M Rigby; M Stewart; A Terry; T Tzavaras
Journal:  Br J Cancer Suppl       Date:  1988-12

5.  Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma.

Authors:  J L Rohn; A S Lauring; M L Linenberger; J Overbaugh
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene.

Authors:  M Stewart; A Terry; M Hu; M O'Hara; K Blyth; E Baxter; E Cameron; D E Onions; J C Neil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

7.  Structure, origin, and transforming activity of feline leukemia virus-myc recombinant provirus FTT.

Authors:  D L Doggett; A L Drake; V Hirsch; M E Rowe; V Stallard; J I Mullins
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Genetic determinants of feline leukemia virus-induced lymphoid tumors: patterns of proviral insertion and gene rearrangement.

Authors:  C Tsatsanis; R Fulton; K Nishigaki; H Tsujimoto; L Levy; A Terry; D Spandidos; D Onions; J C Neil
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Nuclear factor 1 activates the feline leukemia virus long terminal repeat but is posttranscriptionally down-regulated in leukemia cell lines.

Authors:  M Plumb; R Fulton; L Breimer; M Stewart; K Willison; J C Neil
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

10.  Apparent uncoupling of oncogenicity from fibroblast transformation and apoptosis in a mutant myc gene transduced by feline leukemia virus.

Authors:  R Fulton; R Gallagher; D Crouch; J C Neil
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.